Hanmi Pharmaceutical, a core subsidiary of Hanmi Group, said on the 30th that its first-quarter operating profit was provisionally tallied at 53.6 billion won, down 9.1% from a year earlier. Revenue for the same period was 392.9 billion won, up 0.5%.
The company said, "There was a base burden due to a one-off effect from supplying clinical samples to a partner in the same period last year."
However, key products such as the dyslipidemia combination drug "Rosuzet," the hypertension treatment "Amosartan family," and the gastroesophageal reflux disease treatment "Esomezol family" continued steady growth.
First-quarter outpatient prescription sales (based on UBIST) came to 277.6 billion won. Rosuzet rose 9.2% year over year to 59.3 billion won, with Amosartan family at 36.4 billion won and Esomezol family at 14.6 billion won.
Beijing Hanmi Pharmaceutical, the local Chinese subsidiary, posted first-quarter revenue of 106.4 billion won and operating profit of 23.6 billion won. Revenue rose 10.3% and operating profit 107.7% from a year earlier. The sell-down of inventory in China helped improve results.
Hanmi Fine Chemical, an active pharmaceutical ingredient (API) affiliate, recorded first-quarter revenue of 21.7 billion won. Despite intensifying competition in the antibiotic market, operating profit swung to a surplus on the back of increased orders for high-margin contract development and manufacturing (CDMO).
Hanmi Pharmaceutical is developing a pipeline of about 30 innovative new drugs in areas including obesity and metabolic diseases, oncology, and rare diseases, and is strengthening global competitiveness by incorporating new treatment delivery modalities.
In particular, the company is working toward commercializing the glucagon-like peptide (GLP)-1 class obesity drug "Efpeglenatide" within the year, and has formed a companywide council to boost execution.
The holding company Hanmi Science said first-quarter operating profit on a consolidation basis was 33.6 billion won, up 24% from a year earlier. Revenue for the same period rose 6.5% year over year to 353.7 billion won.
The company said balanced performances across the group, including the pharmaceutical wholesale business (Onlinepharm) and its own healthcare business, drove results. Onlinepharm benefited from higher domestic sales centered on ethical drugs (ETC).
A Hanmi Science official said, "These results confirm not only our management capabilities as a holding company but also our ability to generate revenue," adding, "We will maximize synergies among affiliates and strengthen our portfolio across all areas of healthcare to sustain growth."
Hwang Sang-yeon, CEO of Hanmi Pharmaceutical, said, "We will accelerate R&D-centered innovation to leap forward as a global Hanmi," adding, "This year will be an important period in which clinical progress in major new drug development is confirmed."